AZN · Company research
AstraZeneca PLC (AZN): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
53records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| GSK's New Drugs and Pipeline Hold the Key to Long-Term Growth | GSK is focusing on newer specialty medicines and vaccines to offset pressure from older products and drive long-term growth. Recent product launches including Blenrep, Jemperli, and Arexvy are expected to become major revenue contributors, with Blenrep anticipated as a key growth driver over 3-4 years. The company has doubled its phase II and III blockbuster-potential assets since 2022 and expects sales exceeding £40 billion by 2031. However, GSK faces significant competition from major pharmaceutical companies and must navigate patent expirations, particularly in HIV. | View source ↗ | Zacks Investment Research | Oct 20, 2026 | neutral | 0.111 | 1 |
| The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology | Zacks highlights four breast cancer drug stocks for Breast Cancer Awareness Month. AstraZeneca and Roche are established large-cap pharma companies with strong commercial portfolios and pipeline opportunities. Puma Biotechnology relies on Nerlynx sales with a mid-stage pipeline candidate. Olema Oncology is a clinical-stage company dependent on its lead candidate palazestrant's phase III trial results expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 19, 2026 | bullish | 0.333 | 1 |
| 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month | Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.667 | 1 |
| 4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month | Four pharmaceutical and biotech companies are positioned in the breast cancer treatment market with varying growth prospects. AstraZeneca and Roche leverage established drug portfolios with expanding indications, Puma Biotechnology focuses on Nerlynx sales growth, while Olema Oncology awaits pivotal clinical trial results for its lead candidate palazestrant expected in Q1 2027. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 0.667 | 1 |
| Astrazeneca (AZN) Rises Higher Than Market: Key Facts - Yahoo Finance | Astrazeneca (AZN) Rises Higher Than Market: Key Facts Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Astrazeneca (AZN) Rises Higher Than Market: Key Facts | Astrazeneca (AZN) closed at $166.68, up 2.87% in the latest session, outperforming the S&P 500. The pharmaceutical company is trading at a Forward P/E of 17.28, below its industry average of 25.3, suggesting a valuation discount. However, the stock holds a Zacks Rank #3 (Hold) rating with projected Q3 EPS declining 9.24% year-over-year, though full-year earnings are expected to grow 2.4%. The Medical - Biomedical and Genetics industry ranks in the bottom 38% of all industries. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0 | 1 |
| Astrazeneca (AZN) Rises Higher Than Market: Key Facts | Astrazeneca (AZN) closed at $166.68, up 2.87% in the latest session, outperforming the S&P 500. The pharmaceutical company is trading at a Forward P/E of 17.28, below its industry average of 25.3, suggesting a valuation discount. However, the stock holds a Zacks Rank #3 (Hold) rating with projected Q3 EPS declining 9.24% year-over-year, though full-year earnings are expected to grow 2.4%. The Medical - Biomedical and Genetics industry ranks in the bottom 38% of all industries. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0 | 1 |
| Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? | Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.8 | 1 |
| Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? | Gilead Sciences entered a collaboration with Vir Biotechnology to develop three novel T-cell engagers targeting solid tumors. Vir will receive $90 million upfront plus up to $1.74 billion in milestone payments. The deal reflects Gilead's strategy to diversify beyond HIV into oncology, though near-term profitability faces pressure from deal costs and competition from rivals like AstraZeneca and Bristol Myers in cancer therapies. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 0.8 | 1 |
| AstraZeneca PLC Stock (AZN) Moved Up by 3.55% on Oct 15: What Signal Does It Send? - TradingKey | AstraZeneca PLC Stock (AZN) Moved Up by 3.55% on Oct 15: What Signal Does It Send? TradingKey | View source ↗ | TradingKey | Oct 15, 2026 | neutral | 0 | 0.6 |
| AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know - TradingView | AstraZeneca, insitro Strike AI Drug Discovery – What Investors Need To Know TradingView | View source ↗ | TradingView | Oct 15, 2026 | neutral | 0 | 0.6 |
| The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk | Stock markets declined following a higher-than-expected CPI inflation report. Analysts provided research updates on three major stocks: Mastercard benefits from the shift to electronic payments but faces competitive pricing pressure; AstraZeneca struggles with patent expirations and pipeline setbacks despite strong upcoming drugs; SanDisk outperforms due to AI-driven demand for enterprise SSDs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0 | 1 |
| The Zacks Analyst Blog Highlights Mastercard, AstraZeneca and Sandisk | Stock markets declined following a higher-than-expected CPI inflation report. Analysts provided research updates on three major stocks: Mastercard benefits from the shift to electronic payments but faces competitive pricing pressure; AstraZeneca struggles with patent expirations and pipeline setbacks despite strong upcoming drugs; SanDisk outperforms due to AI-driven demand for enterprise SSDs. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | neutral | 0 | 1 |
| AstraZeneca inks AI drug discovery deal with insitro (AZN:NYSE) - Seeking Alpha | AstraZeneca inks AI drug discovery deal with insitro (AZN:NYSE) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| Top Research Reports for Mastercard, AstraZeneca & Sandisk | Zacks analysts published research on 16 major stocks on October 14, 2026. Mastercard received a Neutral rating despite strong performance, citing competitive pricing pressure and premium valuation concerns. AstraZeneca faces patent erosion challenges but benefits from strong pipeline drugs and expects $80 billion in revenues by 2030. SanDisk received an Outperform rating, driven by AI inference demand and strong datacenter exposure. Other notable stocks analyzed include Exelon, General Mills, and Halozyme, with mixed outlooks across various sectors. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.667 | 1 |
| AstraZeneca PLC Stock Draws Upgrades As Oncology Deals Accelerate - StocksToTrade | AstraZeneca PLC Stock Draws Upgrades As Oncology Deals Accelerate StocksToTrade | View source ↗ | StocksToTrade | Oct 14, 2026 | neutral | 0 | 0.6 |
| Why AstraZeneca (AZN) Stock Is Up Today - Quiver Quantitative | Why AstraZeneca (AZN) Stock Is Up Today Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 14, 2026 | neutral | 0 | 0.6 |
| AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis - TradingKey | AstraZeneca PLC Stock (AZN) Moved Up by 3.81% on Oct 14: A Full Analysis TradingKey | View source ↗ | TradingKey | Oct 14, 2026 | neutral | 0 | 0.6 |
| Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? | Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| Will Keytruda Continue to Aid Merck's Top Line in Q3 Earnings? | Merck's blockbuster cancer drug Keytruda generated $16.40 billion in first-half 2026 sales, up 4.2% year-over-year, with expectations for continued growth through 2028 when it reaches peak sales of $35 billion. However, the company faces significant headwinds as biosimilar competition is expected around 2028-2029, which will likely cause sharp sales declines. Merck stock has outperformed the industry year-to-date but currently holds a Zacks Rank #4 (Sell) rating. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 1 |
| AstraZeneca PLC - American Depositary Shares (NYSE:AZN) Stock Quote - FinancialContent | AstraZeneca PLC - American Depositary Shares (NYSE:AZN) Stock Quote FinancialContent | View source ↗ | FinancialContent | Oct 13, 2026 | neutral | 0 | 0.6 |
| AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting - Slideshow (NYSE:AZN) 2026-10-12 - Seeking Alpha | AstraZeneca PLC (AZN) Presents at American Society for Bone and Mineral Research (ASBMR) 2026 Annual Meeting - Slideshow (NYSE:AZN) 2026-10-12 Seeking Alpha | View source ↗ | Seeking Alpha | Oct 12, 2026 | neutral | 0 | 0.6 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Cancer Stocks to Consider as Oncology Innovation Accelerates | The global oncology market is experiencing rapid growth due to rising cancer incidence, aging populations, and medical advances including immunotherapies, targeted medicines, and personalized vaccines. Major pharmaceutical companies are investing heavily in oncology R&D, with innovations in antibody-drug conjugates, bispecific antibodies, and next-generation immunotherapies. Three companies highlighted for oncology exposure are Pfizer, Merit Medical Systems, and Abbott Laboratories. | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 Results | Pfizer's oncology revenues rose 3% to $4.17 billion in Q2 2026, representing 27% of total revenues. The company expects Q3 growth driven by newer drugs like Padcev, Lorbrena, and Braftovi-Mektovi, offset by declines in Ibrance and Adcetris. Pfizer is advancing the dual PD-1/VEGF inhibitor PF-08634404 across nine studies including two pivotal phase III trials. The stock trades at an attractive valuation with a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.667 | 1 |
| How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? | Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| How Is Eli Lilly's Oncology Portfolio Poised Ahead of Q3 Earnings? | Eli Lilly's oncology segment is projected to generate $2.65 billion in Q3 2026 revenues, with growth driven by newer drugs like Jaypirca, Retevmo, and Inluriyo offsetting slower Verzenio sales. The company faces intense competition from AstraZeneca, Merck, and Pfizer in the oncology space. LLY stock has risen 10.6% year-to-date but trades at a premium valuation of 26.80x forward earnings. | View source ↗ | Zacks Investment Research | Oct 8, 2026 | bullish | 0.75 | 1 |
| Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure? - Stocktwits | Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure? Stocktwits | View source ↗ | Stocktwits | Oct 8, 2026 | neutral | 0 | 0.6 |
| AstraZeneca (LSE:AZN) Stock Looks Below Fair Value As Spending Rises - Simply Wall Street | AstraZeneca (LSE:AZN) Stock Looks Below Fair Value As Spending Rises Simply Wall Street | View source ↗ | Simply Wall Street | Oct 7, 2026 | neutral | 0 | 0.6 |
| AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current Earnings - Yahoo Finance | AstraZeneca (LSE:AZN) Stock Looks Reasonable Based On Current Earnings Yahoo Finance | View source ↗ | Yahoo Finance | Oct 7, 2026 | neutral | 0 | 0.6 |
| Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? | Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| Will Linzess Continue to Aid Ironwood's Top-Line Growth in Q3? | Ironwood Pharmaceuticals (IRWD) is experiencing strong prescription demand for its primary product Linzess, with U.S. net profit share surging 72.6% year-over-year in the first half of 2026. The company raised its full-year 2026 revenue guidance to $460-$485 million, citing continued momentum from Linzess sales, recent FDA label expansion for pediatric patients, and favorable pricing dynamics. IRWD stock is trading at a valuation discount to the industry and carries a Zacks Rank #2 (Buy) rating. | View source ↗ | Zacks Investment Research | Oct 7, 2026 | bullish | 0.25 | 1 |
| Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider | Astrazeneca (AZN) closed at $158.61, up 1.33%, outperforming the S&P 500. The pharmaceutical company is expected to report earnings on October 30, 2026, with predicted EPS of $2.16 (down 9.24% YoY) and revenue of $16.07 billion (up 5.82% YoY). AZN holds a Zacks Rank #3 (Hold) with a Forward P/E of 16.71, trading at a discount to its industry average of 22.46. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | neutral | 0 | 1 |
| Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance | Astrazeneca (AZN) Exceeds Market Returns: Some Facts to Consider Yahoo Finance | View source ↗ | Yahoo Finance | Oct 6, 2026 | neutral | 0 | 0.6 |
| Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? | Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| Merck Stock Down 7% in a Month: Is the Dip a Buying Opportunity? | Merck's stock declined 7.2% recently after a strong 60% annual gain, but analysts view this as a healthy pullback. While the company faces near-term headwinds including Gardasil weakness, generic competition, and Keytruda's 2028 patent expiration, its expanding pipeline with 20 new drug launches expected by 2030 and strategic acquisitions position it for long-term growth. The company maintains a Hold rating with potential as a buying opportunity for long-term investors. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.25 | 1 |
| A Massachusetts investment will expand AstraZeneca’s state workforce by over 50% in coming years. - Stock Titan | A Massachusetts investment will expand AstraZeneca’s state workforce by over 50% in coming years. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos | Summit Therapeutics announced a clinical collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway across multiple solid tumors, starting with a phase III study in first-line triple-negative breast cancer. This partnership builds on AstraZeneca's $2 billion investment in Summit announced the previous week, expanding ivonescimab's development pipeline and creating additional clinical and commercial opportunities. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bullish | 0.5 | 1 |
| FDA Expands Eli Lilly's Blood Cancer Drug Label in First-Line Setting | Eli Lilly announced FDA approval for Jaypirca (pirtobrutinib) as a first-line treatment for previously untreated CLL/SLL patients without 17p deletion. The drug reduced disease progression or death risk by 80% versus chemoimmunotherapy in the phase III BRUIN CLL-313 study. Jaypirca sales grew 66% to $357 million in H1 2026, with the drug's non-covalent BTK inhibitor mechanism differentiating it from competitors like Brukinsa, Calquence, and Imbruvica. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | bearish | -0.5 | 1 |
| Cancer-drug partnerships accompany AstraZeneca (AZN)'s completed investment in Summit. - Stock Titan | Cancer-drug partnerships accompany AstraZeneca (AZN)'s completed investment in Summit. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| AstraZeneca has put $2 billion into Summit to support work on an experimental cancer treatment. - Stock Titan | AstraZeneca has put $2 billion into Summit to support work on an experimental cancer treatment. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| AZN 261016 210.00C (AZN261016C210000) Stock Options Chain | Quotes & News - Moomoo | AZN 261016 210.00C (AZN261016C210000) Stock Options Chain | Quotes & News Moomoo | View source ↗ | Moomoo | Oct 4, 2026 | neutral | 0 | 0.6 |
| Sanofi, Regeneron Expand Immunology Alliance With New Antibodies | Sanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.667 | 1 |
| Sanofi, Regeneron Expand Immunology Alliance With New Antibodies | Sanofi and Regeneron have expanded their longstanding alliance to co-develop four next-generation long-acting antibodies targeting type II inflammation. Regeneron will receive $1 billion upfront and up to $7 billion in milestone payments, with both companies equally sharing development costs and future profits. The collaboration builds on their successful Dupixent partnership, which generated €9.3 billion in sales in H1 2026 and is projected to reach €25 billion by 2030. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.667 | 1 |
| Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity | Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| Europe Cancer Metabolism Based Therapeutics Market Forecast to 2035 by Modality, Route, Indication, and Therapy Sales | 25.3% CAGR Drives an $8.54 Billion Opportunity | Europe's cancer metabolism-based therapeutics market is projected to grow from $1.12 billion in 2026 to $8.54 billion by 2035, representing a 25.3% CAGR. Growth is driven by Europe's high cancer burden, advances in molecular profiling, precision oncology adoption, and regulatory validation. Small molecules and oral administration routes dominate, with breast cancer and non-small cell lung cancer as leading indications. Key players include AstraZeneca, Bayer, Novartis, Roche, and Servier. | View source ↗ | GlobeNewswire Inc. | Oct 2, 2026 | bullish | 1 | 1 |
| DaltonTx, the decision engine for drug discovery, launches advanced AI-powered antibody discovery platform | DaltonTx announced the launch of advanced antibody discovery capabilities within its Dalton platform, which integrates AI models for antibody design, structure prediction and validation. The platform can evaluate millions of antibody sequences and help researchers identify promising candidates more efficiently by combining AI outputs with experimental data and expert judgment. | View source ↗ | GlobeNewswire Inc. | Oct 1, 2026 | neutral | 0 | 1 |
| A $2 Billion Reason Why AstraZeneca Stock Is Down Today - Yahoo Finance | A $2 Billion Reason Why AstraZeneca Stock Is Down Today Yahoo Finance | View source ↗ | Yahoo Finance | Sep 29, 2026 | neutral | 0 | 0.6 |
| AstraZeneca (LSE:AZN) Stock May Be 48% Undervalued On Enhertu Trial Progress - Yahoo Finance | AstraZeneca (LSE:AZN) Stock May Be 48% Undervalued On Enhertu Trial Progress Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
| AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks - Yahoo Finance | AZN Stock Down 20% in 6 Months: How to Play After Pipeline Setbacks Yahoo Finance | View source ↗ | Yahoo Finance | Sep 2, 2026 | neutral | 0 | 0.6 |
| Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance | Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know Yahoo Finance | View source ↗ | Yahoo Finance | Jul 20, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.